Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fusaric acid is a **picolinic acid derivative** and a **mycotoxin** produced by fungi of the Fusarium genus[4][8]. It acts as an **antibiotic and plant wilting agent**, and has been explored as a **medical research tool** but is not approved for clinical use. Its main mechanism of action is the **inhibition of dopamine beta-hydroxylase**, the enzyme responsible for converting dopamine to norepinephrine, which impacts catecholamine biosynthesis in humans[1][4][7][9]. This can result in blood pressure reduction and potential symptom relief in diseases such as pheochromocytoma and contributes to its potential antineoplastic/anticancer activities by inducing cytotoxic effects and oxidative damage in cancer cells[3][10]. Fusaric acid has also been studied for its effects on neurotransmitter metabolism and cell cycle arrest[3][7]. It is primarily used experimentally and as a biochemical tool in research; it is toxic and not approved for routine human administration[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fusaric acid.